Form 4: Scholar Rock Executive Executes Sell-to-Cover Transaction

Scholar Rock President of R&D Akshay Vaishnaw sold 12,246 shares to satisfy tax obligations related to RSU vesting.

Summary

• Akshay Vaishnaw, President of R&D at Scholar Rock Holding Corp, sold 12,246 shares of common stock.
• The transaction occurred on April 16, 2026, at an average price of $49.5745 per share.
• The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations following the vesting of restricted stock units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine, non-discretionary tax compliance measure rather than a signal of management's outlook.

Positives

• The transaction was non-discretionary and mandated by the company's equity incentive plan, indicating no change in management sentiment regarding the company's future.

Negatives

• The sale reduces the executive's direct holdings, though it remains a routine tax-related event.

Risks

• Future vesting of 450,000 performance-based RSUs remains subject to continued service and performance conditions.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an insider transaction.

Management Comments

• The sale was mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice in the biotechnology sector, where equity-based compensation is a significant component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for publicly traded biotech firms.
• The use of mandatory sell-to-cover programs is consistent with policies at peers like Alnylam Pharmaceuticals or Ionis Pharmaceuticals.

Stakeholder Impact

• No material impact on shareholders as the transaction was non-discretionary.

Next Steps

• Continued service of the reporting person to satisfy remaining vesting conditions for outstanding RSUs.

Key Dates

Keywords

Scholar Rock, SRRK, Insider Trading, Form 4, Biotech, Equity Compensation